# Calcific coronary stenosis in patient with supra-annular transcatheter heart valve



Male, 93-y.o.

• DM, hypertension, dyslipidemia



#### Past medical history


- 1990 total prostatectomy
- Claudicatio intermittens Leriche-Fontain IIa
- 2016 Acute coronary syndrome (ACS-NSTEMI) treated by medical therapy
- 11/2021 Traumatic syncope → severe aortic stenosis
- 12/2021 permanent pacemaker implantation
- Early 12/2022 Cardiogenic shock → Three vessels coronary disease, severe aortic stenosis (Mean Gradient 60 mmHg) → TAVR with CoreValve Evolut R
- End 12/2022 PCI+3 drug eluting stent (DES) on LM-LAD, residual CTO of non dominant Cx, and severe right coronary (RCA) stenosis





#### Active medical status

- Admission in ED for acute pulmonary edema and dyspnea
- EKG: ST depression in V2-V5
- Myocardial damage markers (first sample): Tnl 130 ng/L (n.r. <14), CK-MB 11,6 ng/ml (n.r. < 6,2)

# Angiography









#### **Predictors of impaired CA after TAVR**



Non-aligned supra-annular THV (OR 4.59, 95% CI 1.81-11.61, p<0.01)



**THV-Sinus of Valsalva relation** (OR 1.06, 95% CI 1.02-1.1, p<0.01)



**Sinus of Valsalva height** (OR 0.83, 95% CI 0.7-0.98, p=0.03)

## **Invasive treatment**

GC JR4: ineffective
GC AR1: effective with low-support


Guidewire: workhorse → extra-support


3,0x15 mm Non-compliant (NC) balloon: uncrossable lesion

GC extension

2,5x10 mm Cutting balloon

3,0x15 mm NC balloon (22 atm): dog-bone






## **Invasive treatment**

3,0x12 mm lithotripsy

3,0x15 mm NC balloon

3,0x18 mm DES

3,0x15 mm Post-dilatation



# **Conclusions and learning points**

- A careful consideration about the completeness of myocardial revascularization should be done in patients with aortic valve stenosis and coronary artery disease, particularly in elderly population with a high risk of bleeding in case of urgent revascularization for acute coronary syndrome.
- A prosthetic aortic valve with supra-annular design has a potential challenging coronary re-access issue that carries longer procedural time and higher contrast administration.

